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Summary. Dramatical development of molecular 
genetics has been disclosing the molecular mechanism 
of Duchenne muscular dystrophy (DMD) and Becker 
muscular dystrophy (RMD). DMD gene product, 
dystrophin, is a submembranous cytoskeletal protein and 
many dystrophin-associated proteins (DAPs) have been 
identified, such as utrophin, dystroglycans, sarcoglycans, 
syntrophins and dystrobrevins. Dystrophin and DAPs are 
very important proteins not only for skeletal, cardiac, or 
smooth muscles but also for peripheral and central 
nervous systems including the retina. The retina has 
been extensively examined to demonstrate that 
dystrophin and B-dystroglycan localize at the 
photoreceptor terminal, and their deficiency produces 
the abnormal neurotransmission between photoreceptor 
cells and ON-bipolar cells. Dystrophin has seven 
isoforms in variable tissues, and the retina contains full- 
length dystrophin (Dp427), Dp260, and Dp71. Recent 
studies have demonstrated that Dp71 localizes in the 
inner limiting membrane (INL) and around the blood 
vessel, and Dp260 is expressed in the outer plexiform 
layer (OPL). B-dystroglycan is also expressed in the 
same regions as well as dystrophin, but it remains 
unclear whether other DAPs are expressed in the retina 
or not. It is generally assumed that dystrophin functions 
to stabilize muscle fibers with DAPs by linking the 
sarcolemma to the basement membrane, but its function 
in the retina is totally unknown so far. 
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die with respiratory insufficiency by around 20 years 
old. Another prominent symptom is a non-progressive 
cognitive impairment, which approximately 30% of 
patients with DMD have. In addition, although no visual 
disturbance had been reported in the past several 
decades, recent physiological s tudies  using 
electroretinograms (ERGS) have clarified that abnormal 
ERGS develop in some DMDJRMD patients (Cibis et al., 
1993; Pillers et al., 1993; Fitzgerald et al., 1994; 
Sigesmund et al., 1994). Dystrophin, a lacking protein in 
DMD patients,  is localized not only under the 
sarcolemma of skeletal, cardiac, or smooth muscle fibers 
(Arahata et al., 1988; Watkins et al., 1988; Zubrzycka- 
Gaarn et al., 1988) but also in the central nervous system 
(Lidov et al., 1990, 1993; Jung et al., 1991), peripheral 
nerves (Byers et al., 1993), and retinas (Miike et al., 
1989; Zhao et al., 1991; Schmitz et al., 1993; Ueda et al., 
1995, 1997a,b). Most of our current knowledge about 
dystrophin in synaptic regions is based on the studies of 
neuromuscular junctions (NMJs),  which have no 
neuronal postsynaptic components. So it does not seem 
precisely to apply the knowledge obtained from the NMJ 
to other synapses. The retina is one of relatively easily- 
handled tissues for examination of the synaptic function 
and structure in the central nervous system. Since some 
excellent reviews have been published on the 
biochemical aspects of dystrophin and DAPs (Ahn and 
Kunkel, 1993; Ozawa et al., 1995, 1998; Henry and 
Campbell, 1996; Ohlendieck, 1996; Durbeej et al., 1998) 
and on the retina1 dystrophin (Schmitz and Drenckhahn, 
1997b), in this review we summarize recent knowledge 
about dystrophin and DAPs in the retina. 
Introduction Dystrophin and utrophin 
Both DMD and BMD are X-linked recessive lethal Dystrophin has several spliced variants which are 
disorders with a worldwide incidence of 1 in 3500 male transformed from the large dystrophin gene, Xp21. Full- 
births (Moser, 1984). The most striking clinical feature length dystrophin in muscle tissues such as skeletal, 
is skeletal muscle weakness, and usually DMD patients cardiac, or smooth muscles has a 427kDa molecular 
weight (M-dystrophin; Dp427), consisting of a-actinin- 
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